Manal,
First, I should mention what I have said many times. No one should plan on using the same chelator for a life time because all chelators have long term side effects, and it's advised to switch chelators at some point.
As far as Exjade, with every new update, we hear about new problems with Exjade. I recently posted the latest about Exjade at
http://www.thalassemiapatientsandfriends.com/index.php?topic=3390.msg34628#msg34628 Some items of note:
(Exjade)... may cause renal, hepatic and gastrointestinal damage...this warning indicates that deferasirox may cause renal and hepatic impairment and/or failure and gastrointestinal hemorrhage. Reactions were severe enough to be fatal in some patients....
"Expert thalassemia centers and clinicians have known about these risks before the warning was added to the Exjade label. Fortunately, most thalassemia patients are young compared to the older adults who had severe or fatal outcomes to Exjade use. However, in the thalassemia population, stomach and duodenal ulcers, bleeding, liver and kidney problems have been noted, and therefore close monitoring is suggested. Also fortunately, most thalassemia patients who take Exjade do so without these unwanted side effects."
These are the type of problems that only get worse over time. In addition, we must pay attention to the fact that hundreds of older patients (mainly Myelodysplastic syndrome patients, who generally are older) have died while on an Exjade regimen. We do not hear this about the other chelators, in spite of various problems associated with these chelators. I don't think anyone should get into a panic, but I do think that older patients need to weigh their health condition, especially liver and kidney health, before starting on Exjade. As far as a case like Lena's, I agree with Lena that we just don't know enough about the use of Exjade at low iron levels to know how safe it is. Meanwhile, Ferriprox has a long established record and honestly, the deaths mentioned in the same breath as Ferrirpox are deaths that happened because Ferriprox was NOT available to the patients and not from using Ferriprox. Lisa was one of these statistics.
My other main concern is that patients in developing nations often do not have access to the close monitoring required with Exjade, yet the drug is being introduced into these countries with the full knowledge that monitoring will not always be what it should be. If the Big Pharma giant is going to introduce this drug into these situations, they should also open up their fat wallets to help the local treatment centers fully understand and fund monitoring compliance.